Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE:002099)
China flag China · Delayed Price · Currency is CNY
5.21
-0.26 (-4.75%)
Sep 10, 2026, 3:04 PM CST

SHE:002099 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,9561,8511,9222,1632,6982,477
Other Revenue
2.7910.1216.439.146.397.99
1,9581,8611,9382,1722,7042,485
Revenue Growth
7.32%-4.01%-10.75%-19.68%8.83%0.54%
Cost of Revenue
1,5851,5011,5951,9832,0241,602
Gross Profit
373.58359.92343.72189.17680.2882.35
Selling, General & Admin
363.57327.51329.6345.07407.92563.71
Research & Development
112.19116.93129.45115.56144.91164.64
Other Operating Expenses
19.0815.7911.679.4311.7126.73
Operating Expenses
496.35463.06475.26456.65582.06765.17
Operating Income
-122.77-103.14-131.53-267.4798.14117.18
Interest Expense
-12.21-27.25-28.8-37.76-36.55-21.89
Interest & Investment Income
132.5106.4264.6368.1333.4736.34
Currency Exchange Gain (Loss)
-28.44-26.1335.032.81107.95-30.28
Other Non Operating Income (Expenses)
-29.31-1.65-2.02-1.85-2.4-1.03
EBT Excluding Unusual Items
-60.23-51.74-62.68-236.15200.62100.31
Impairment of Goodwill
---208.47-107.69-46.73-
Gain (Loss) on Sale of Investments
-32.45-31.97-35.24-117.62-45.686.46
Gain (Loss) on Sale of Assets
-0.170.031.0412.880.29-1.48
Asset Writedown
-77.431.57-34.38-25.13-13.420.55
Other Unusual Items
-0.97-1.992.867.55.7317.18
Pretax Income
-171.24-84.09-336.88-466.22100.8123.03
Income Tax Expense
-0.369.66-2.99-44.6414.7329.17
Earnings From Continuing Operations
-170.88-93.75-333.89-421.5886.0893.87
Minority Interest in Earnings
1.672.683.621.531.941.36
Net Income
-169.21-91.08-330.27-420.0688.0195.23
Net Income to Common
-169.21-91.08-330.27-420.0688.0195.23
Net Income Growth
-----7.58%-70.21%
Shares Outstanding (Basic)
1,6141,5181,5731,6161,7601,587
Shares Outstanding (Diluted)
1,6141,5181,5731,6161,7601,587
Shares Change
21.81%-3.48%-2.66%-8.22%10.91%-0.71%
EPS (Basic)
-0.10-0.06-0.21-0.260.050.06
EPS (Diluted)
-0.10-0.06-0.21-0.260.050.06
EPS Growth
-----16.67%-70.00%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-90.93-134.1452.7387.46-63.33-127.2
Free Cash Flow Per Share
-0.06-0.090.030.05-0.04-0.08
Dividend Per Share
----0.0500.100
Dividend Growth
-----50.00%400.00%
Gross Margin
19.08%19.34%17.73%8.71%25.15%35.51%
Operating Margin
-6.27%-5.54%-6.78%-12.31%3.63%4.72%
Profit Margin
-8.64%-4.90%-17.04%-19.34%3.26%3.83%
Free Cash Flow Margin
-4.64%-7.21%2.72%4.03%-2.34%-5.12%
EBITDA
211.13232.83206.792.7429.78406.32
EBITDA Margin
10.78%12.51%10.66%4.27%15.89%16.35%
D&A For EBITDA
333.9335.97338.23360.17331.64289.14
EBIT
-122.77-103.14-131.53-267.4798.14117.18
EBIT Margin
-6.27%-5.54%-6.78%-12.31%3.63%4.72%
Effective Tax Rate
----14.61%23.71%
Revenue as Reported
935.531,8611,9382,1722,7042,485
Advertising Expenses
-3.722.992.790.210.64